A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
23 08 2023
Historique:
received: 29 03 2021
accepted: 03 08 2023
medline: 25 8 2023
pubmed: 24 8 2023
entrez: 23 8 2023
Statut: epublish

Résumé

To date, single-nucleotide polymorphisms (SNPs) have been the most intensively investigated class of polymorphisms in genome wide associations studies (GWAS), however, other classes such as insertion-deletion or multiple nucleotide length polymorphism (MNLPs) may also confer disease risk. Multiple reports have shown that the 5p15.33 prostate cancer risk region is a particularly strong expression quantitative trait locus (eQTL) for Iroquois Homeobox 4 (IRX4) transcripts. Here, we demonstrate using epigenome and genome editing that a biallelic (21 and 47 base pairs (bp)) MNLP is the causal variant regulating IRX4 transcript levels. In LNCaP prostate cancer cells (homozygous for the 21 bp short allele), a single copy knock-in of the 47 bp long allele potently alters the chromatin state, enabling de novo functional binding of the androgen receptor (AR) associated with increased chromatin accessibility, Histone 3 lysine 27 acetylation (H3K27ac), and ~3-fold upregulation of IRX4 expression. We further show that an MNLP is amongst the strongest candidate susceptibility variants at two additional prostate cancer risk loci. We estimated that at least 5% of prostate cancer risk loci could be explained by functional non-SNP causal variants, which may have broader implications for other cancers GWAS. More generally, our results underscore the importance of investigating other classes of inherited variation as causal mediators of human traits.

Identifiants

pubmed: 37612286
doi: 10.1038/s41467-023-40616-z
pii: 10.1038/s41467-023-40616-z
pmc: PMC10447552
doi:

Substances chimiques

Chromatin 0
Nucleotides 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

5118

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023. Springer Nature Limited.

Références

Nat Med. 2015 Nov;21(11):1357-63
pubmed: 26398868
Genome Biol. 2011 Aug 22;12(8):R83
pubmed: 21859476
Hum Mol Genet. 2015 Oct 1;24(19):5589-602
pubmed: 26025378
Nat Commun. 2017 Feb 09;8:14385
pubmed: 28181482
Nat Genet. 2015 Nov;47(11):1346-51
pubmed: 26457646
Nature. 2008 May 1;453(7191):56-64
pubmed: 18451855
Nature. 2008 Nov 6;456(7218):60-5
pubmed: 18987735
Genome Biol. 2008;9(9):R137
pubmed: 18798982
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
BMC Bioinformatics. 2016 Oct 3;17(1):404
pubmed: 27716038
Nat Genet. 2011 Jun;43(6):513-8
pubmed: 21614091
Nucleic Acids Res. 2014 Jul;42(13):8310-9
pubmed: 24981513
PLoS Genet. 2010 Apr 01;6(4):e1000888
pubmed: 20369019
Hum Mol Genet. 2005 Jan 1;14(1):59-69
pubmed: 15525656
Nat Rev Genet. 2009 Sep;10(9):595-604
pubmed: 19636342
Nat Methods. 2015 Nov;12(11):1061-3
pubmed: 26366987
Genome Res. 2001 Jan;11(1):170-8
pubmed: 11156626
Am J Hum Genet. 2002 Oct;71(4):854-62
pubmed: 12205564
Endocrinology. 1999 Nov;140(11):5054-9
pubmed: 10537131
JCI Insight. 2019 Oct 3;4(19):
pubmed: 31503550
Eur J Hum Genet. 2014 Apr;22(4):558-63
pubmed: 24022300
Dev Biol. 2000 Jan 15;217(2):266-77
pubmed: 10625552
Genetics. 2007 May;176(1):403-7
pubmed: 17409076
Nat Rev Genet. 2015 Mar;16(3):172-83
pubmed: 25645873
PLoS Genet. 2014 May 15;10(5):e1004383
pubmed: 24830394
Nature. 2015 Jul 23;523(7561):486-90
pubmed: 26083756
Cell. 2018 Jul 26;174(3):576-589.e18
pubmed: 30033361
Nat Genet. 2014 Oct;46(10):1103-9
pubmed: 25217961
Genome Res. 2014 Jan;24(1):1-13
pubmed: 24196873
Nat Genet. 2022 Sep;54(9):1364-1375
pubmed: 36071171
Nat Commun. 2018 Jun 11;9(1):2256
pubmed: 29892050
Nature. 2015 Nov 12;527(7577):192-7
pubmed: 26375006
Cancer Res. 2021 Jan 15;81(2):282-288
pubmed: 33115802
Wellcome Open Res. 2019 Oct 1;4:145
pubmed: 31976378
Nat Genet. 2020 Aug;52(8):790-799
pubmed: 32690948
Hum Mol Genet. 2012 May 1;21(9):2076-85
pubmed: 22323358
Nature. 2009 Aug 20;460(7258):1011-5
pubmed: 19587683
Nat Genet. 2018 Apr;50(4):538-548
pubmed: 29632383
Genome Biol. 2015 Sep 17;16:195
pubmed: 26381377
Nucleic Acids Res. 2019 Jan 8;47(D1):D729-D735
pubmed: 30462313
Gene Ther. 2012 Nov;19(11):1058-64
pubmed: 22113311
Science. 2012 Sep 7;337(6099):1190-5
pubmed: 22955828
Genome Res. 2012 Sep;22(9):1748-59
pubmed: 22955986
Nature. 2008 Nov 6;456(7218):66-72
pubmed: 18987736
Nat Commun. 2019 Apr 16;10(1):1784
pubmed: 30992455
Nature. 2000 Sep 28;407(6803):516-20
pubmed: 11029003
Hum Mol Genet. 2014 Oct 1;23(19):5294-302
pubmed: 24907074
Nat Genet. 2018 Jul;50(7):928-936
pubmed: 29892016
Hum Mol Genet. 2015 Oct 1;24(19):5603-18
pubmed: 26162851
Nat Genet. 2017 May;49(5):692-699
pubmed: 28369037
Nat Commun. 2020 May 27;11(1):2539
pubmed: 32461613
Methods Mol Biol. 2016;1418:335-51
pubmed: 27008022
Nat Methods. 2017 Dec;14(12):1163-1166
pubmed: 29083402

Auteurs

Sandor Spisak (S)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

Viktoria Tisza (V)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Computational Health Informatics Program (CHIP) Boston Children's Hospital Harvard Medical School, Boston, MA, 02215, USA.
Institute of Enzymology, Research Centre for Natural Sciences, Budapest, 1117, Hungary.

Pier Vitale Nuzzo (PV)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Lgo R. Benzi 10, 16132, Italy.

Ji-Heui Seo (JH)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

Balint Pataki (B)

Department of Physics of Complex Systems, ELTE Eötvös Loránd University, Pázmány P. s. 1A, Budapest, 1117, Hungary.

Dezso Ribli (D)

Department of Physics of Complex Systems, ELTE Eötvös Loránd University, Pázmány P. s. 1A, Budapest, 1117, Hungary.

Zsofia Sztupinszki (Z)

Computational Health Informatics Program (CHIP) Boston Children's Hospital Harvard Medical School, Boston, MA, 02215, USA.

Connor Bell (C)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

Mersedeh Rohanizadegan (M)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

David R Stillman (DR)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

Sarah Abou Alaiwi (SA)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

Alan H Bartels (AH)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

Marton Papp (M)

Institute of Enzymology, Research Centre for Natural Sciences, Budapest, 1117, Hungary.
Centre for Bioinformatics, University of Veterinary Medicine, Istvan str. 2, Budapest, 1078, Hungary.

Anamay Shetty (A)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Division of Genetics, Brigham & Women's Hospital, Boston, MA, USA.

Forough Abbasi (F)

Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.

Xianzhi Lin (X)

Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.

Kate Lawrenson (K)

Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Center for Bioinformatics and Functional Genomics, Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.

Simon A Gayther (SA)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Center for Bioinformatics and Functional Genomics, Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.

Mark Pomerantz (M)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.

Sylvan Baca (S)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
The Eli and Edythe L. Broad Institute, Cambridge, MA, 02142, USA.

Norbert Solymosi (N)

Department of Physics of Complex Systems, ELTE Eötvös Loránd University, Pázmány P. s. 1A, Budapest, 1117, Hungary.

Istvan Csabai (I)

Department of Physics of Complex Systems, ELTE Eötvös Loránd University, Pázmány P. s. 1A, Budapest, 1117, Hungary.

Zoltan Szallasi (Z)

Computational Health Informatics Program (CHIP) Boston Children's Hospital Harvard Medical School, Boston, MA, 02215, USA.
Department of Bioinformatics, Forensic and Insurance Medicine Semmelweis University, Budapest, Hungary.
Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark.
National Korányi Institute of Pulmonology, Budapest, 1112, Hungary.

Alexander Gusev (A)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Division of Genetics, Brigham & Women's Hospital, Boston, MA, USA.
The Eli and Edythe L. Broad Institute, Cambridge, MA, 02142, USA.

Matthew L Freedman (ML)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. matthew_freedman@dfci.harvard.edu.
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. matthew_freedman@dfci.harvard.edu.
The Eli and Edythe L. Broad Institute, Cambridge, MA, 02142, USA. matthew_freedman@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH